Sunday, November 8, 2026

USD/CNH Bearish Momentum With A 2% Drop In The Last 21 Sessions

ViaNews Editorial Team

December 8, 2023

USD/CNH Bearish Momentum With A 2% Drop In The Last 21 Sessions

(VIANEWS) - USD/CNH (USDCNH) has been up by 2.28% for the last 21 sessions. At 05:15 EST on Friday, 8 December, USD/CNH (USDCNH) is $7.15.

USD/CNH's yearly highs and lows, it's 0.008% up from its 52-week low and 0.161% down from its 52-week high.

News about

  • Usd/jpy analysis: the impact on the policy change of the Japanese central bank - 07 December 2023. According to DailyForex on Thursday, 7 December, "Furthermore, the future performance of USD/JPY depends on the reaction to the announcement of US jobs numbers tomorrow. ", "For three consecutive weeks, the USD/JPY has been subjected to profit-taking selloffs since testing the resistance level of 151.90, its highest in over a year, in the middle of last month. "
  • Usd/jpy trades better bid above 147.00 after dovish boj commentary. According to FXStreet on Wednesday, 6 December, "Further, a minor rebound in the US Treasury bond yields is helping the USD/JPY to stay afloat amid a retreat in the US Dollar across the board. ", "The swift US Dollar rebound lifted USD/JPY from daily lows of 146.56, as the pair went on to settle Tuesday almost unchanged at 147.20. "
  • Usd/jpy sticks close to 147.50 heading into the back half of the trading week. According to FXStreet on Wednesday, 6 December, "The USD/JPY is seeing thin trading heading into the back half of the trading week, holding near the 147.50 level ahead of Thursday's US Initial Jobless Claims that will give way to Friday's Japanese Gross Domestic Product (GDP) and the latest US Nonfarm Payrolls (NFP) report that will cap off the trading week.", "The USD/JPY is seeing thin, tight trading near the 147.50 level, with near-term bids getting propped up north of 146.00 while also constrained by the 148.00 handle to the topside."
  • Usd/jpy drops on its worst day in over a year, breaches 142.00. According to FXStreet on Thursday, 7 December, "The USD/JPY is on pace to see it's single worst trading day since November of 2022 after plunging over four percent on Thursday with a broad-market rally for the Japanese Yen (JPY). ", "The USD/JPY has accelerated towards the downside, pulling away from intraday levels and pinning near-term technical indicators deep in oversold territory. "
  • According to Business Insider on Thursday, 7 December, "As the Fed cuts rates and the BoJ starts to raise, FX markets could see a long-term driver of USD/JPY gains begin to fade as the carry trade becomes more risky.", "We doubt USD/JPY will start correcting well in advance before the Fed's first rate cut, given the magnitude of carry," said Shusuke Yamad, FX and rates strategist at Bank of America."

More news about USD/CNH (USDCNH).

In this story · Knowledge Files

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biotech Catalyst Season: Regulatory Deadlines and Data Readouts Against Cost Discipline and Slipping Timelines
From late October 2026 to January 2027, mid-cap biotechs cluster pivotal data presentations (ESMO, AHA, AASLD), FDA decision dates (ivonescimab BLA on 2026-11-14, lorundrostat on 2026-12-22) and Q3 earnings. Alongside these, several companies are managing capital: lowering R&D and SG&A guidance, pushing clinical milestones into 2027, authorizing a $400M buyback, and pursuing a delisting. Late-stage programs in oncology, hepatitis delta, hypertension and women's health look near commercial inflection, while cost cuts and delays point to uneven balance-sheet strength.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,996
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,996 facts checked against source5,552 source documents archived
Query this data → isubstrate.com